Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi AppTec Leads Investment in Insilico, an AI Drug Discovery Company

publication date: Jun 11, 2018

WuXi AppTec's Corporate Venture Fund led a financing in Insilico Medicine, a Baltimore artificial intelligence company specializing in target identification, drug discovery and aging research. WuXi plans to integrate Insilico's AI technology into its own CRO drug discovery offerings. The investment is conditional upon experimental validation of Insilico's Generative Adversarial Networks (GAN) and Reinforcement Learning (RL)-based drug discovery pipeline. The size of the financing was not disclosed. More details....

Stock Symbol: (SHA: 603259)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital